BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its target price reduced by research analysts at HC Wainwright from $47.00 to $43.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 46.86% from the […]
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 16,230,000 shares, a growth of 7.7% from the April 15th total of 15,070,000 shares. Currently, 11.5% of the company’s stock are sold short. Based on an […]
BridgeBio Pharma (NASDAQ:BBIO) Upgraded to "Strong-Buy" by Evercore ISI themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.